atlas pharmacy LLC

92-13 jamaica ave.
woodhaven, new york 11427

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 15, 2013

NYS DOS ID#
4487689

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - ATLAS PHARMACY LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
    Tuesday Jun 13, 2017

    Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.

    Source: The Wall Street Journal: U.S. Business
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Boston Tech Watch: Ticketmaster, Accomplice, Jebbit & More
    By Jeff Engel - Friday Aug 11, 2017

    Time to catch up on more New England tech news. This week, we’re tracking acquisitions by a division of Ticketmaster, new funding for a trio of local companies, and the latest on the makeover of Accomplice’s venture investing team. Read on for details. Changing hands —Ticketmaster-owned TicketWeb is buying Strobe Labs, a startup that provides […]

    Source: Xconomy VC, Deals, & Startups Feed
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York